Evaluation of glycine-bearing celecoxib derivatives as a colon-specific mutual prodrug acting on nuclear factor-κB, an anti-inflammatory target

Sunyoung Lee, Yonghyun Lee, Wooseong Kim, Joon Nam, Seongkeun Jeong, Jin Wook Yoo, Min Soo Kim, Hyung Ryong Moon, Yunjin Jung

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

In an inflammatory state where HOCl is generated, glycine readily reacts with HOCl to produce glycine chloramine, an anti-inflammatory oxidant. Colonic delivery of celecoxib elicits anticolitic effects in a trinitrobenzene sulfonic acid-induced rat colitis model. Glycine-bearing celecoxib derivatives were prepared and evaluated as a colon-specific mutual prodrug acting on nuclear factor-κB (NFκB), an anticolitic target. Glycylcelecoxib (GC), N-glycylaspart-1-ylcelecoxib (N-GA1C), and C-glycylaspart-1-ylcelecoxib (C-GA1C) were synthesized and their structures identified using infrared and proton nuclear magnetic resonance spectrometer. The celecoxib derivatives were chemically stable in pH 6.8 and 1.2 buffers. GC and C-GA1C were resistant to degradation in the small intestinal contents, while N-GA1C was substantially cleaved to release celecoxib. In contrast, all the celecoxib derivatives were degraded to liberate celecoxib in the cecal content. These results suggest that GC and C-GA1C could be delivered to and liberate celecoxib and glycine in the large intestine. In human colon carcinoma HCT116 and murine macrophage RAW264.7 cells, combined celecoxib–glycine chloramine treatment additively suppressed the production of proinflammatory NFκB target gene products. Collectively, our data suggest that C-GA1C is a potential colon-specific mutual prodrug acting against NFκB.

Original languageEnglish
Pages (from-to)4227-4237
Number of pages11
JournalDrug Design, Development and Therapy
Volume9
DOIs
StatePublished - 7 Aug 2015

Keywords

  • Celecoxib
  • Colon-specific drug delivery
  • Glycine chloramine
  • Mutual prodrug
  • Nuclear factor kappa-B

Fingerprint

Dive into the research topics of 'Evaluation of glycine-bearing celecoxib derivatives as a colon-specific mutual prodrug acting on nuclear factor-κB, an anti-inflammatory target'. Together they form a unique fingerprint.

Cite this